Marc S. Raab
Marc S. Raab
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Oral selinexor–dexamethasone for triple-class refractory multiple myeloma
A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ...
New England Journal of Medicine 381 (8), 727-738, 2019
Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma
MA Dimopoulos, D Dytfeld, S Grosicki, P Moreau, N Takezako, M Hori, ...
New England Journal of Medicine 379 (19), 1811-1822, 2018
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
K Neben, HM Lokhorst, A Jauch, U Bertsch, T Hielscher, B van der Holt, ...
Blood, The Journal of the American Society of Hematology 119 (4), 940-948, 2012
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, FE Davies, ...
Blood, The Journal of the American Society of Hematology 132 (6), 587-597, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, F Davies, ...
Leukemia 33 (1), 159-170, 2019
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
J Moreaux, FW Cremer, T Reme, M Raab, K Mahtouk, P Kaukel, ...
Blood 106 (3), 1021-1030, 2005
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
I Breitkreutz, MS Raab, S Vallet, T Hideshima, N Raje, C Mitsiades, ...
Leukemia 22 (10), 1925-1932, 2008
Multiple myeloma: patient outcomes in real‐world practice
K Yong, M Delforge, C Driessen, L Fink, A Flinois, S Gonzalez‐McQuire, ...
British journal of haematology 175 (2), 252-264, 2016
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del (17p), t (4; 14), gain 1q, hyperdiploidy, and tumor load
K Neben, A Jauch, T Hielscher, J Hillengass, N Lehners, A Seckinger, ...
Journal of clinical oncology 31 (34), 4325-4332, 2013
Targeting the BRAF V600E Mutation in Multiple MyelomaBRAF in Myeloma
M Andrulis, N Lehners, D Capper, R Penzel, C Heining, J Huellein, ...
Cancer discovery 3 (8), 862-869, 2013
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
KM Kortüm, EK Mai, NH Hanafiah, CX Shi, YX Zhu, L Bruins, S Barrio, ...
Blood, The Journal of the American Society of Hematology 128 (9), 1226-1233, 2016
Combining information regarding chromosomal aberrations t (4; 14) and del (17p13) with the International Staging System classification allows stratification of myeloma patients …
K Neben, A Jauch, U Bertsch, C Heiss, T Hielscher, A Seckinger, T Mors, ...
Haematologica 95 (7), 1150, 2010
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
H Goldschmidt, HM Lokhorst, EK Mai, B van der Holt, IW Blau, ...
Leukemia 32 (2), 383-390, 2018
STIL is required for centriole duplication in human cells
J Vulprecht, A David, A Tibelius, A Castiel, G Konotop, F Liu, F Bestvater, ...
Journal of cell science 125 (5), 1353-1362, 2012
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
EK Mai, U Bertsch, J Dürig, C Kunz, M Haenel, IW Blau, M Munder, ...
Leukemia 29 (8), 1721-1729, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose …
PG Richardson, S Jagannath, P Moreau, AJ Jakubowiak, MS Raab, ...
The Lancet Haematology 2 (12), e516-e527, 2015
The immunogenic glycoprotein gp35-37 of human herpesvirus 8 is encoded by open reading frame K8. 1
MS Raab, JC Albrecht, A Birkmann, S Yağuboğlu, D Lang, ...
Journal of virology 72 (8), 6725-6731, 1998
Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics
FW Cremer, J Bila, I Buck, M Kartal, D Hose, C Ittrich, A Benner, MS Raab, ...
Genes, Chromosomes and Cancer 44 (2), 194-203, 2005
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615. HCl)
K Podar, MS Raab, J Zhang, D McMillin, I Breitkreutz, YT Tai, BK Lin, ...
Blood 109 (4), 1669-1677, 2007
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells
K Mahtouk, D Hose, T Rème, J De Vos, M Jourdan, J Moreaux, G Fiol, ...
Oncogene 24 (21), 3512-3524, 2005
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20